Table 2.
Primary and Secondary Outcomes of patients in case-control group (N=20) and Dornase alfa treatment group (N=10).
| Primary and Secondary Outcomes | |||
|---|---|---|---|
| Control (N = 20) | Dornase alfa (N = 10) | P-Value | |
| Primary Outcomes | |||
| ΔPaO2/FiO2 from Day 0 (95% CI) | |||
| Day 1 | -0.8 to 43.6 | -29.7 to 51.1 | 0.59 |
| Day 2 | -9.6 to 33.1 | 5.2 to 117 | 0.04 |
| Day 3 | -9.7 to 34.7 | -21 to 68 | 0.59 |
| Day 4 | -24.8 to 31.7 | -21.8 to 70.1 | 0.38 |
| Day 5 | -28.8 to 38.8 | -35.9 to 111 | 0.32 |
| Day 14 | -92.6 to 70.2 | -150.8 to 260.8 | 0.38 |
| Secondary Outcomes | |||
| Δ Lung compliance from Day 0 (95% CI) | |||
| Day 1 (mL/cmH2O) | -4.2 to 3.9 | -1.7 to 7.9 | 0.28 |
| Day 2 | -3.1 to 2.3 | -1 to 9 | 0.08 |
| Day 3 | -9.8 to -1.6 | -0.8 to 13.3 | <0.01 |
| Day 4 | -9.4 to -1.8 | -3.2 to 11.3 | <0.01 |
| Day 5 | -8.4 to -1.3 | -1.8 to 16.6 | <0.01 |
| Day 14 | -17.9 to -2.4 | -16.3 to 17.8 | 0.09 |
| Δ PEEP from Day 0 (95% CI) | |||
| Day 1 (cmH2O) | -0.7 to 1.7 | -0.8 to 1.2 | 0.74 |
| Day 2 | -0.8 to 1.7 | -1.7 to 0.9 | 0.34 |
| Day 3 | -1.1 to 2.4 | -3.1 to 1.3 | 0.27 |
| Day 4 | -1.6 to 2.2 | -4.5 to 1.6 | 0.28 |
| Day 5 | -1.4 to 3.1 | -5.5 to 2 | 0.19 |
| Days on Mechanical Ventilation* | 18.2 (8-38) | 15.2 (5-29) | 0.47 |
| Days in ICU* | 22.1 (11-47) | 16.5 (7-30) | 0.23 |
| Days of Hospitalization* | 28.7 (15-60) | 22.5 (8-52) | 0.61 |
| Secondary Pulmonary Infections** | 5 (25%) | 3 (30%) | 0.78 |
| Mortality, 28-day** | 9 (45%) | 4 (40%) | 0.8 |
| Mortality, 90-day** | 11 (55%) | 4 (40%) | 0.46 |
*(mean, min to max) **(total and % of patient population). ICU, Intensive Care Unit. Significant P-values are in bold.